Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn's Disease: The OPERA II Study.
Geert R D'HaensWalter ReinischScott D LeeDino TarabarEdouard LouisMaria KłopockaJochen KlausStefan SchreiberDong Il ParkXavier HébuternePeter NagyFabio CataldiSteven W MartinSatyaprakash NayakAnindita BanerjeeKenneth J GorelickWilliam J SandbornPublished in: Inflammatory bowel diseases (2021)
Ontamalimab was well tolerated; treatment responses appeared to be sustained over 72 weeks.ClinicalTrials.gov ID: NCT01298492.
Keyphrases